Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 11, 2010, Pages 972-978

  Beste, Lauren A ^a   Ioannou, George N ^a,b   Larson, Meaghan S ^a   Chapko, Michael ^a,c   Dominitz, Jason A ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hepatology; Treatment Attrition; Treatment Duration; Viral Hepatitis

Indexed keywords

CREATININE; HEMOGLOBIN; HEMOPOIETIC GROWTH FACTOR; PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DEPRESSION; DIABETES MELLITUS; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; GENOTYPE 1 HEPATITIS C; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERONS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; TIME FACTORS; VIREMIA;

EID: 77958465477     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.07.012     Document Type: Article

References (24)

1. Armstrong G.L., Wasley A., Simard E.P. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
2. Dominitz J.A., Boyko E.J., Koepsell T.D., et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 2005, 41:88-96.
3. Backus L.I., Boothroyd D.B., Phillips B.R., et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007, 46:37-47.
4. Fumaz C.R., Munoz-Moreno J.A., Ballesteros A.L., et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 2007, 19:138-145.
5. Chew K.W., Allen S.A., Taylor L.E., et al. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C [Erratum in: 2009;43:1010]. J Clin Gastroenterol 2009, 43:686-691.
6. Lee S.S., Bain V.G., Peltekian K., et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006, 23:397-408.
7. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
8. Backus L.I., Gavrilov S., Loomis T.P., et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009, 16:775-783.
9. VHA Office of Productivity Efficiency, and Staffing. FY08 Physician Productivity by Specialty Accessed August 19, 2009. http://opes.vssc.med.va.gov.
10. Szabo C.R. Veterans Health Administration NLB Human Resources Committee 2005 Facility Complexity Model 2005, Veterans Health Administration, Washington, DC.
11. Butt A.A., McGinnis K.A., Skanderson M., et al. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010, 30:240-250.
12. Evon D.M., Verma A., Simpson K., et al. Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. Aliment Pharmacol Ther 2008, 27:1071-1080.
13. Huckans M., Mitchell A., Ruimy S., et al. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull 2010, 36:165-172.
14. Chainuvati S., Khalid S.K., Kancir S., et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat 2006, 13:235-241.
15. Huckans M.S., Loftis J.M., Blackwell A.D., et al. Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders. Subst Abuse Treat Prev Policy 2007, 2:4.
16. Robaeys G., Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol Belg 2005, 68:55-67.
17. Dore G.J., Hellard M., Matthews G., et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010, 138:123-135. e1-e2.
18. Iacobellis A., Ippolito A., Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008, 14:6467-6472.
19. Elgouhari H.M., Zein C.O., Hanouneh I., et al. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009 Jan 16, [Epub ahead of print].
20. Steiner J.F., Koepsell T.D., Fihn S.D., et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988, 26:814-823.
21. Elixhauser A., Eisen S.A., Romeis J.C., et al. The effects of monitoring and feedback on compliance. Med Care 1990, 28:882-893.
22. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
23. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
24. Goulet J.L., Fultz S.L., McGinnis K.A., et al. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. Aids 2005, 19(Suppl 3):S99-S105.